價格 | ¥331 | ¥495 |
包裝 | 50mg | 100mg |
最小起訂量 | 1mg |
發(fā)貨地 | 上海 |
更新日期 | 2025-02-28 |
中文名稱:N-(2-羥乙基)腺苷 | 英文名稱:N6-(2-Hydroxyethyl)adenosine |
CAS:4338-48-1 | 品牌: TargetMol |
產(chǎn)地: 美國 | 保存條件: Shipping with blue ice. |
純度規(guī)格: 99.4% | 產(chǎn)品類別: 抑制劑 |
貨號: TNU0429 |
名稱 | N6-(2-Hydroxyethyl)adenosine |
描述 | N6-(2-Hydroxyethyl)adenosine is a Ca2+ antagonist and anti-inflammatory agent that is associated with the control of cerebral and coronary circulation and is thought to possess sedative activity. |
體外活性 | N6-(2-Hydroxyethyl)adenosine can suppress TGF-β1 or LPS-induced TGF-β1/Smad and NF-κB signaling pathways in vitro. The levels of ECM production, indicated by expression of collagen I, α-SMA and Fibronectin, are significantly reduced by treatment with N6-(2-Hydroxyethyl)adenosine dose-dependently (5, 10, and 20 μg/ml). Similarly, TGF-β and LPS stimulate increased levels of TNF-α, IL-1β and IL-10. N6-(2-Hydroxyethyl)adenosine treatment reduces the elevated levels of TNF-α and IL-1β and increases IL-10 secretion dose-dependently [1]. |
體內(nèi)活性 | Injury of Kidney Tissue in UUO Mice Ameliorated by Intraperitoneal Administration of N6-(2-Hydroxyethyl) adenosine (2.5, 5, and 7.5 mg/kg; intraperitoneal injection). N6-(2-Hydroxyethyl) adenosine treatment prevents the accumulation of fibrosis-related proteins (TGF-β1, α-SMA, collagen I, and Fibronectin) and inflammatory cytokines (TNF-α, IL-6, IL-1β, and IL-10) associated with renal interstitial fibrosis. N6-(2-Hydroxyethyl) adenosine could block the accumulation of M1 macrophages, and induced the accumulation of M2 macrophages in ligated kidneys [1]. |
存儲條件 | Shipping with blue ice. |
溶解度 | DMSO : 4.8 mg/mL (15.42 mM) |
相關(guān)產(chǎn)品 | Nisoldipine | 1-Octanol | Levetiracetam | 2-Nitrobenzoic acid | Otilonium bromide | Ethyl cinnamate | Diltiazem hydrochloride | Lanthanum(III) chloride heptahydrate | L-Ascorbic acid | Nimodipine | Methyl homoveratrate | 1,2,4-Trihydroxybenzene |
相關(guān)庫 | 神經(jīng)保護化合物庫 | 經(jīng)典已知活性庫 | 已知活性化合物庫 | 神經(jīng)信號分子庫 | 抗衰老化合物庫 | 離子通道庫 | 膜蛋白靶向化合物庫 | 疼痛相關(guān)化合物庫 |
成立日期 | 2013-04-18 (13年) | 注冊資本 | 566.265100萬人民幣 |
員工人數(shù) | 100-500人 | 年營業(yè)額 | ¥ 1億以上 |
主營行業(yè) | 天然產(chǎn)物,生化試劑,分子生物學(xué),分子砌塊,生物技術(shù)服務(wù) | 經(jīng)營模式 | 貿(mào)易,工廠,試劑,定制,服務(wù) |
產(chǎn)品名稱 | 價格 | 公司名稱 | 報價日期 | |
---|---|---|---|---|
詢價 |
VIP7年
|
湖北阡陌生物科技有限公司
|
2025-04-24 | |
詢價 |
VIP3年
|
湖北魏氏化學(xué)試劑股份有限公司
|
2025-04-24 | |
詢價 |
VIP1年
|
陜西西化化學(xué)工業(yè)有限公司
|
2025-03-14 |